Beyond lowering blood glucose levels and inducing weight loss in individuals with type 2 diabetes mellitus, sodium–glucose cotransporter 2 (SGLT2) inhibitors are associated with protective renal and cardiovascular effects. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.